Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

Share Price is delayed by 15 minutes
Get Live Data
22.50    0.00 (0.00%)
Bid:
21.00
Ask:
24.00
Spread: 3.00 (14.286%)
Market Cap: £233.50m
SCLP Live PriceLast checked at - London Stock Exchange

Intraday Scancell Holdings Share Chart

BLOCK LISTING SIX MONTHLY RETURN

16 Feb 2021 15:00

RNS Number : 2924P
Scancell Holdings Plc
16 February 2021
 

Scancell Holdings Plc

("Scancell" or the "Company")

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 16 February 2021

 

 

Name of applicant:

Scancell Holdings plc

Name of scheme:

Convertible Loan Notes Shares

 

Period of return:

From:

12 August 2020

To:

15 February 2021

Number of securities originally admitted at date of admission

96,774,193 ordinary shares of £0.001 each

12 August 2020

 

Balance of unallotted securities under scheme(s) from previous return:

96,774,193 ordinary shares of £0.001 each

 

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

69,719,566 ordinary shares of £0.001 each

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

27,054,627 ordinary shares of £0.001 each

 

 

 

 

 

 

 

Name of contact:

Dr Cliff Holloway, CEO

Telephone number of contact:

+44 (0) 20 3727 1000

 

For Further Information:

 

Scancell Holdings plc

 

 

Dr John Chiplin, Chairman

 

+44 (0) 20 3727 1000

Dr Cliff Holloway, CEO

 

 

 

 

 

Panmure Gordon (UK) Limited

 

 

Freddy Crossley/Emma Earl (Corporate Finance)

 

+44 (0) 20 7886 2500

Rupert Dearden (Corporate Broking)

 

 

 

 

 

FTI Consulting

 

 

Simon Conway/Natalie Garland-Collins

 

+44 (0) 20 3727 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRZQLFFFLLEBBV
Date   Source Headline
28th Apr 20267:00 amRNSFDA Fast Track Designation for iSCIB1+
2nd Apr 20267:00 amRNSScancell announces CFO transition
29th Jan 20267:00 amRNSHalf-year Financial Report
26th Jan 20267:00 amRNSFDA clearance of IND application for iSCIB1+
22nd Jan 20267:00 amRNSNotice of Results
9th Dec 20257:00 amRNSContinued improvement in PFS with iSCIB1+
7th Nov 20257:00 amRNSResearch Update
30th Oct 20253:30 pmRNSResult of AGM
3rd Oct 20257:00 amRNSNotice of AGM
16th Sep 20257:00 amRNSDirector Dealing
11th Sep 20257:00 amRNSFinal Results
4th Sep 20257:00 amRNSNotice of Results
8th Aug 202512:31 pmRNSDirector Dealing
4th Aug 202510:23 amRNSDirector/PDMR Shareholding
22nd Jul 20257:00 amRNSStrong Phase 2 data on iSCIB1+ in Melanoma
16th Jul 20257:00 amRNSShare Option Exercise
25th Jun 20257:00 amRNSScancell initiates new arm in SCOPE Phase 2 study
21st May 20257:00 amRNSDirector Dealing
14th Apr 20257:00 amRNSPartnership with NHS Cancer Vaccine Launch Pad
1st Apr 20257:00 amRNSScancell to present at 2025 AACR Annual Meeting
20th Feb 20257:00 amRNSIssue of share options
17th Feb 20257:00 amRNSScancell presenting at AACR IO conference
30th Jan 20257:00 amRNSInterim Results
23rd Jan 20257:00 amRNSNotice of Interim Results
9th Jan 20257:00 amRNSModi-1 Vaccine Achieves Early Clinical Validation
9th Dec 202411:41 amRNSResult of Retail Offer and Total Voting Rights
5th Dec 202412:39 pmRNSResult of Placing and Subscription
4th Dec 20246:03 pmRNSRetail Offer for up to £1 million
4th Dec 20245:59 pmRNSProposed fundraise in excess of £8.5 million
4th Dec 20247:00 amRNSSecond Commercial License Agreement with Genmab
18th Nov 20247:00 amRNSPositive data from Phase 2 SCOPE trial with SCIB1
25th Oct 20243:26 pmRNSResult of Annual General Meeting
24th Oct 20247:00 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSScancell Appoints Dr Phil L’Huillier as CEO
1st Oct 20247:00 amRNSNotice of AGM
24th Sep 20247:00 amRNSResults Year Ended 30 April 2024
18th Sep 20247:00 amRNSNotice of Final Results
17th Sep 20247:00 amRNSStrategic Partnership with PharmaJet
2nd Sep 20247:00 amRNSScancell to attend upcoming conferences
30th Jul 20247:17 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
30th Jul 20247:00 amRNSScancell Appoints Dr Nermeen Varawalla as CMO
24th Jul 20247:00 amRNSUpdate from iSCIB1+ Clinical Advisory Meeting
10th Jul 20247:00 amRNSAppointment of Dr Florian Reinaud to the Board
2nd Jul 20247:00 amRNSExtension of Convertible Loan Notes
1st Jul 20247:00 amRNSBlock Listing Return and Total Voting Rights
21st Jun 20247:00 amRNSChange of Nominated Advisor
12th Jun 20247:32 amRNSAgreement with major biotech
31st May 20247:00 amRNSScancell to attend upcoming conferences
30th May 20247:00 amRNSUpdate on ModiFY trial
24th May 20247:00 amRNSScancell to present at ASCO Annual Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.